
Patricia Pérez-Galán
Publicacions destacades
-
Patient-derived follicular lymphoma spheroids recapitulate lymph node signaling and immune profile uncovering galectin-9 as a novel immunotherapeutic target
Autors:Referència: Blood Cancer Journal 2024. -
Patient-derived lymphoma spheroids integrating immune tumor microenvironment as preclinical follicular lymphoma models for personalized medicine
Autors:Referència: Journal For Immunotherapy Of Cancer 2023. -
A novel patient-derived 3D model recapitulates mantle cell lymphoma lymph node signaling, immune profile and in vivo ibrutinib responses
Autors:Referència: Leukemia 2023. -
The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma
Autors:Referència: Leukemia 2021. -
3D Model Characterization by 2D and 3D Imaging in t(14;18)-Positive B-NHL: Perspectives for In Vitro Drug Screens in Follicular Lymphoma
Autors:Referència: Cancers 2021. -
PI3Kδ inhibition reshapes follicular lymphoma-immune microenvironment cross talk and unleashes the activity of venetoclax
Autors:Referència: Blood Advances 2020. -
Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens
Autors:Referència: Haematologica 2020. -
The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-κB mutational status
Autors:Referència: Haematologica 2017. -
The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia
Autors:Referència: Clinical Cancer Research 2017. -
Disruption of Follicular Dendritic Cells-Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib)
Autors:Referència: Clinical Cancer Research 2014.
Projectes destacats
-
Red transpirenaica de terapias avanzadas en linfoma no Hodgkin (THERAVLINFO)
Investigador/a principal: Patricia Pérez GalánFinançador: Institut d'Investigacions Biomèdiques August Pi i Sunyer (Entidad de origen); POCTEFA-INTERREG, European UnionCodi: EFA 123/1Durada: 01/01/2024 - 31/12/2025 -
Vascularized lymphoma on-chip: a multifaceted tool for translational research (MyLymphoTool)
Investigador/a principal: Patricia Pérez GalánFinançador: Institut d'Investigacions Biomèdiques August Pi i Sunyer (Entidad de origen); Fundació La CaixaCodi: HR22-00395Durada: 01/12/2022 - 30/11/2025 -
Dual CD19-CAR-T approaches to counteract antigen escape and tumor microenvironment immune suppression in FL
Investigador/a principal: Patricia Pérez GalánFinançador: Institut d'Investigacions Biomèdiques August Pi i Sunyer (Entidad de origen); Follicular Lymphoma FoundationCodi: INT_Milken_FLF_22Durada: 01/12/2022 - 30/11/2024 -
Vascular and extracellular matrix remodeling in follicular lymphoma: implications in the transformation to an aggressive lymphoma and immunotherapy efficacy (VASCEM_LYMPHO)
Investigador/a principal: Patricia Pérez GalánFinançador: Institut d'Investigacions Biomèdiques August Pi i Sunyer (Entidad de origen); Agencia Estatal de Investigacion (AEI)Codi: PID2021-124894OB-I00Durada: 01/09/2022 - 31/08/2025 -
Patient Derived Organoids 2.0: Annotated immunocompetent organoid platforms in solid and hematological tumors as living labs for the optimization and design of current and novel immunotherapies and cellular therapies. CIBERONC (Strategic Action-Towards Ca
Investigador/a principal: Patricia Pérez GalánDurada: 01/07/2021 - 01/07/2023